<DOC>
	<DOCNO>NCT02084160</DOCNO>
	<brief_summary>The objective study : - To evaluate ability Methacetin Breath Test ( MBT ) detect hepatic decompensation event - To evaluate relationship liver Biopsy clinical outcome show MBT well predictive ability clinical outcome liver biopsy . - To evaluate ability MBT predict individual liver related complication .</brief_summary>
	<brief_title>Prediction Value BreathID 13C-Methacetin Breath Test Hepatic Decompensation</brief_title>
	<detailed_description>Exalenz previously gather information previous study patient chronic liver disease include methacetin breath test . Several year later , company wish investigate group subject see retrospectively breath test predictor complication relate liver disease .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>All subject aere enrol previous Exalenz trial HISEX408</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>